Question 1

My PBM dropped Zepbound mid-year — can that be fought?

Accepted Answer

★ Often, yes, and the reason it happened matters to the argument. Caremark moved Zepbound off its standard commercial formulary from 1 July 2025 and put Wegovy in the preferred slot. That was a rebate decision between the benefit manager and the manufacturer, not a clinical judgment about the drug — and saying so plainly is the basis of the appeal. ⚠ Two routes exist. A formulary exception applies where the preferred alternative is medically inappropriate for you; separately, most states have continuity-of-care rules covering someone already stable on a non-preferred drug. ⛔ The strongest files are specific: prior failure on the preferred drug with dates and the actual reaction, plus contraindications ruling out the other alternatives. Some members have had the same molecule approved under its diabetes brand while the obesity brand stayed denied, which tells you the decision is about the label, not the chemistry. Your state insurance department publishes the exception forms.

Question 2

Does Medicare cover any of these for weight loss?

Accepted Answer

⛔ Not for weight loss as such. Part D has been barred from covering drugs used for weight reduction since the 2003 Medicare Modernization Act, which is why the obesity indications sit off standard formularies. ★ Two doors are open anyway. The diabetes labels — Ozempic, Mounjaro — are covered on that indication, and since 2024 Wegovy is covered for adults who have established heart disease alongside excess weight. That route exists because SELECT showed a 20% reduction in major adverse cardiac events, and CMS confirmed the indication to Part D plans in March 2024. ⚠ So a beneficiary qualifying today generally needs documented cardiovascular disease, a prescription written for Wegovy specifically, and that drug on their plan's formulary. ⚠ CMS has also announced a route to bring obesity coverage to Medicare at a low monthly cost from 2026. It had not taken effect when this page was written, and the terms have already shifted once — confirm the current position with CMS or your plan rather than planning around it.

Question 3

What does a prior authorization actually need to contain?

Accepted Answer

★ Four things, and denials usually turn on the one people skip. Commercial policies for tirzepatide or semaglutide in obesity generally want a current BMI of 30 or more — or 27 alongside something weight-related, meaning high blood pressure, diabetes, abnormal lipids, sleep apnea or heart disease; enrollment in a structured weight-management program covering diet and activity; a baseline and target weight; and prescriber attestation that no labeled contraindication applies, medullary thyroid carcinoma and MEN-2 history in particular. ⛔ The missing piece in most 'insufficient documentation' denials is the lifestyle-program record. ★ What people have attached successfully: dietitian notes, gym records, food-logging exports, or simply six months of PCP weight checks. That requirement is not arbitrary — both labels position the drug alongside a reduced-calorie diet and more activity, and plans read the labeling literally. ⚠ If the internal appeal fails, state insurance commissioners run an external route.

Question 4

They cut me off because the drug worked — my BMI is under 30 now?

Accepted Answer

⚠ This is a plan rule, not a label rule, and the distinction is your argument. Several commercial policies carry continuation criteria demanding the member's BMI stay at or above the qualifying threshold, or that they show at least 5% reduction from baseline. ⛔ The FDA labeling does not require continuing obesity to continue treatment: Wegovy is indicated on INITIAL BMI, and the cardiovascular indication carries no upper BMI limit at all. ★ The evidence that makes the medical-necessity case is the withdrawal data. In SURMOUNT-4, participants who had lost about 20.9% over 36 weeks were split between continuing tirzepatide and switching to placebo; over the following year the placebo group regained about 14% while those who continued lost a further 5.5%. Losing the qualifying BMI is what the drug is for, and stopping predictably undoes it. ⚠ A common approach is to resubmit coded for obesity history plus the active comorbidity rather than on current BMI alone.

Question 5

Can I use the manufacturer cash price if I am on Medicare or Tricare?

Accepted Answer

★ Yes — and this is the one place where public coverage helps rather than hurts, because the cash channel and the savings card are different things with different rules. The self-pay vial program is open to anyone without coverage for the drug, which includes people whose commercial plan excludes weight-loss drugs and people on Medicare or Tricare whose plans do not cover it. ⛔ The savings CARD is the opposite: federal anti-kickback rules restrict it to commercial insurance, and Medicare, Medicaid, Tricare and VA beneficiaries cannot use it. Confusing the two is why people assume they are shut out of both. ⚠ Published self-pay pricing for the tirzepatide vials has run $349 for the starting dose and $499 for higher doses at the one-month tier, lower per month if you prepay a quarter. Those tiers have been repriced more than once. Check the manufacturer's own page on the day you buy rather than trusting any figure quoted to you, including this one.

Question 6

What is step therapy, and how do I get an exception?

Accepted Answer

★ Step therapy makes you fail a cheaper drug before the plan pays for the one you were prescribed. For GLP-1s that usually means phentermine, Qsymia, Contrave, Saxenda or orlistat first — or Wegovy before Zepbound. ⚠ Every ERISA and ACA-marketplace plan must run a documented exception process, and roughly 30 states legislate the grounds. Those grounds are consistent: the preferred drug is expected to be ineffective given your clinical picture; it has caused or is likely to cause harm; you already tried it and it failed; or you are stable on the current drug already. ★ The fourth is the one people forget, and it is the easiest to evidence. ⛔ What wins is specificity — the prescriber files the exception form with chart notes naming each prior trial, its dates and its outcome. The labels themselves often supply the 'likely to cause harm' ground, since a contraindication such as uncontrolled hypertension with Qsymia is printed there in black and white.

Question 7

Does Ozempic need a particular A1C to stay approved?

Accepted Answer

⚠ The plan wants one; the label does not. Most commercial and Part D policies ask for documented type 2 diabetes with an A1C of 6.5% or higher somewhere in the record, or fasting glucose at 126 mg/dL or above twice, mirroring the diagnostic criteria. ★ The label sets no A1C floor — it positions the drug alongside diet and exercise to improve blood sugar in adults who have type 2 diabetes, and says nothing about a number to stay under. The threshold is a utilization-management rule the plan added, which is exactly why it can be argued with. ⛔ And the argument that matters most: if your latest A1C is under 6.5% BECAUSE the drug is working, that is not grounds to stop it. Most plans will continue on the strength of the original diagnosis and the fact that you are being treated for it, and stopping therapy that reached its target is the opposite of what guidelines advise. ⚠ For weight without diabetes, Ozempic is off-label and generally not covered — semaglutide for obesity is sold as Wegovy.

Question 8

The PA was approved and the copay is still $600 — how?

Accepted Answer

★ Because approval and price are two different decisions. A prior authorization only says the plan accepts the prescription as medically necessary; what you pay is set separately by the formulary tier. ⚠ These drugs commonly land on specialty or non-preferred specialty tiers, which can mean 25-50% coinsurance up to your out-of-pocket maximum, or a flat $200-$700 per fill. On a high-deductible plan you pay the full deductible first, which is why a January fill can run $700-$1,200 on a plan that covers the drug completely by June. ★ Three fixes are worth trying in order: run the manufacturer savings card alongside the insurance, move to 90-day mail order where cost-sharing is often lower, and pay with FSA or HSA dollars so the copay is pre-tax. ⛔ The card is off-limits on Medicare, Medicaid, Tricare and VA under federal anti-kickback rules — those patients should compare the manufacturers' cash channels instead.

Question 9

Does Medicaid cover these for weight loss where I live?

Accepted Answer

⚠ It depends entirely on your state, and this is the answer most likely to be out of date by the time you read it. Federal law does not require state Medicaid programs to cover anti-obesity drugs, so each one decides. As of 2025 roughly a dozen states covered the obesity indications under fee-for-service — California, Pennsylvania, Massachusetts, Michigan, Minnesota and Virginia among them — while others covered the same molecules for diabetes only, or pushed obesity coverage onto managed-care plans. ★ Worth knowing: the Part D weight-loss exclusion does NOT bind Medicaid, so a state is free to cover anti-obesity drugs even though Medicare historically could not. ⛔ For type 2 diabetes, coverage of Ozempic and Mounjaro is close to universal, because federal rebate rules oblige states to cover FDA-approved drugs from participating manufacturers. ⚠ Check your state's Preferred Drug List on the Medicaid agency site — that document, not this page, is the one your pharmacy bills against.

Question 10

Is appealing a first denial worth the effort?

Accepted Answer

★ Yes, and the reason is unflattering to the system: most people never appeal, so a denial is often the last word simply because nobody pushed back. Denials are overturned at internal review often enough to be worth the paperwork, and more often again at independent external review. ⚠ Your appeal rights come from the Affordable Care Act, which guarantees marketplace and most employer plans a review inside the plan first, then an outside reviewer the plan does not control once that first review goes against you. ⛔ What actually reverses a decision, in rough order: adding comorbidity documentation that was missing, adding named prior failures with dates and outcomes, attaching the label language showing the drug is indicated for your diagnosis, and getting a peer-to-peer call between your prescriber and the plan's medical director. ★ If you have the matching condition, the trial to cite is the one for that condition — SELECT for cardiovascular disease, SURMOUNT-OSA for sleep apnea, SUMMIT for heart failure with preserved ejection fraction, SYNERGY-NASH for MASH.

GLP-1 Coverage: the 10 Questions People Ask After a Denial

Q1.My PBM dropped Zepbound mid-year — can that be fought?

Q2.Does Medicare cover any of these for weight loss?

Q3.What does a prior authorization actually need to contain?

Q4.They cut me off because the drug worked — my BMI is under 30 now?

Q5.Can I use the manufacturer cash price if I am on Medicare or Tricare?

Q6.What is step therapy, and how do I get an exception?

Q7.Does Ozempic need a particular A1C to stay approved?

Q8.The PA was approved and the copay is still $600 — how?

Q9.Does Medicaid cover these for weight loss where I live?

Q10.Is appealing a first denial worth the effort?

References

Questions and answers